Regeneron Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
REGN Regeneron Pharmaceuticals Inc
NSC Norfolk Southern Corp
WM Waste Management Inc
ITOS Iteos Therapeutics Inc
CCLD CareCloud Inc
JEF Jefferies Financial Group Inc
RSASF Resaas Services Inc
VRNT Verint Systems Inc
TRHC Tabula Rasa HealthCare Inc
ILMN Illumina Inc

Health Care : Biotechnology | Large Cap Blend
Company profile

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. It also provides Expresse service assurance and CloudCheck WiFi experience management solutions.

Day's Change
-8.77 (-1.12%)
B/A Size
Day's High
Day's Low
(Below Average)

Today's volume of 578,555 shares is on pace to be lower than REGN's 10-day average volume of 724,147 shares.


Cisco's stock rises on strong quarterly sales and guidance, but a restructuring is coming

8:29 am ET November 17, 2022 (MarketWatch)

By Jon Swartz

Cisco Systems Inc.'s stock rose in extended trading Wednesday after the networking-technology company delivered better-than-expected numbers on the top and bottom line, and offered encouraging guidance.

Still, Cisco Chief Financial Officer Scott Herren announced a "limited business restructuring," to be shared with employees on Thursday, that will right-size its real-estate portfolio and impact about 5% of its 80,000 workers worldwide -- or 4,000 people. "This is about rebalancing across the board," he said, adding that as many jobs will be added as reduced.

"Our goal is to minimize the number of people who end up having to leave," Herren told MarketWatch. "We will match as many with new roles at the company as we can. This is not about reducing our workforce -- in fact we'll have roughly the same number of employees at the end of this fiscal year as we had when we started."

Cisco (CSCO)reported a fiscal first-quarter net income of $2.7 billion, or 65 cents a share, compared with net income of $3 billion, or 70 cents a share, in the year-ago quarter. Adjusted earnings were 86 cents a share. Revenue was $13.6 billion, up 6% from $12.9 billion a year ago.

Analysts surveyed by FactSet had expected on average net income of 84 cents a share on revenue of $13.3 billion. Shares gained 4% in after-hours trading following the results, after closing down 1% in regular trading Wednesday at $44.39.

"Our fiscal 2023 is off to a good start as we delivered the largest quarterly revenue and second-highest quarterly non-GAAP earnings per share in our history," Cisco Chief Executive Chuck Robbins said in a statement announcing the results. During a conference call with analysts late Wednesday, Robbins noted "modest improvement" in component delivery amid an easing supply-chain pipeline.

Cisco's Product ($10.25 billion) and Service ($3.39 billion) businesses were up slightly year over year. Secure, Agile Networks, the company's top business segment including data-center networking switches, hauled in $6.68 billion, up 12% from a year ago.

Herren recognized buying caution in Europe driven by a dramatic increase in energy costs and market volatility. The company has also shut down operations in Russia.

For the fiscal second quarter, Cisco executives guided for 84 cents to 86 cents a share in adjusted profit and revenue growth of 4.5% to 6.5%. Analysts were forecasting adjusted earnings of 85 cents and revenue of $13.24 billion, according to FactSet.

Shares of Cisco Systems have dwindled 30% this year, while the broader S&P 500 index has tailed off 17%.

In the days leading up to Cisco's report, financial analysts had expected results and guidance in line with their modest expectations but warned of lingering supply-chain woes.

"We model 15-20% declines in orders [year-over-year] due to tough compares a year ago and stronger seasonality last quarter, but backlog should protect revenues for now," Barclays analyst Tim Long said in a note to investors on Tuesday.

-Jon Swartz


(END) Dow Jones Newswires

November 17, 2022 08:29 ET (13:29 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.